Drug intelligence / Profile preview

ABSK121-NX

Development stage: Phase 1
Lead developer: Abbisko Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ABSK121-NX is an oral pan-FGFR (fibroblast growth factor receptor) inhibitor being developed for the treatment of advanced solid tumors. It specifically targets FGFR2 and has activity against resistance mutations. The drug works by inhibiting FGFR signaling, which potentially decreases tumor cell proliferation and inhibits tumor growth. It is currently being investigated in Phase 1 clinical trials.

Targets

FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on ABSK121-NX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABSK121-NX.

Explore the full profile